Career Enhancement Program
职业提升计划
基本信息
- 批准号:10268748
- 负责人:
- 金额:$ 8.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-03 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:Acral Lentiginous Malignant MelanomaAddressAwarenessBasal Cell CancerCancer CenterCancer Research ProjectCareer MobilityClinicalCutaneous MelanomaDepartment chairDevelopmentEnsureFacultyFinancial SupportFosteringFoundationsFundingFunding AgencyFutureGoalsGrantInstitutesLaboratoriesLeadershipMeasuresMelanoma CellMentorsMentorshipMinorityMonitorOralOutcomePaperPeer ReviewPennsylvaniaPoliciesPositioning AttributeProceduresProgress ReportsPublicationsPublishingResearchResearch PersonnelResearch Project GrantsResourcesSkin CancerSolidSquamous CellTalentsThe Wistar InstituteTrainingTraining SupportTranslational ResearchUnderrepresented MinorityUniversitiesWomanWorkanticancer researchcancer subtypescareercareer developmentdiversity and inclusionexpectationhealth disparityhigh standardinnovationinterestinvestigator trainingmeetingsmelanomamembernext generationprogramsrecruitresearch and developmentsuccesstranslational cancer researchtranslational research programtranslational scientist
项目摘要
Project Summary – Career Enhancement Program
The goal of the Career Enhancement Program (CEP) is to recruit, train and retain a diverse pool of outstanding
early-career investigators who are committed to pursuing translational skin cancer research. The CEP will be led
by two established investigators with complementary expertise in basic (Dr. Villanueva) and clinical (Dr.
Schuchter) melanoma research. Both co-Directors are committed to training and mentoring of translational
investigators and have an established record of recruiting and supporting women and minorities. The CEP will
primarily assist junior faculty in their career development, but more established investigators interested in
refocusing their research efforts on melanoma/skin cancer could also be considered. Women and
underrepresented minorities will be strongly encouraged to participate. Likewise, projects aimed at addressing
health disparities and/or skin cancer subtypes more common in underrepresented minorities will be encouraged
and given special consideration. A team of clinicians, educators and researchers with broad expertise in
translational research will ensure implementation of the specific aims of this program. With the support of the
University of Pennsylvania, the Abramson Cancer Center and The Wistar Institute, the CEP will provide junior
faculty the resources and guidance needed to establish innovative and fully funded independent skin cancer
research programs and become future academic leaders. The CEP will provide awardees with two years of
financial support for translational research projects in skin cancer with potential promotion to full SPORE projects
or independent grant support. Awardees are required to actively participate in SPORE functions, use the SPORE
Core resources, and provide both formal written progress reports and oral presentations. We have established
high standards and expectations for the research mentors and a formalized program of long-term awardee
mentorship. The program measures success by resulting publications, funding, and ultimately career
advancement and national recognition. We have an outstanding talent pool of candidates and an effective
training and mentorship program that will result in an exceptional group of skin cancer researchers. Our SPORE
CEP has had an outstanding record recruiting and training investigators for careers in translational skin cancer research.
Our past CEP awardees have published 74 papers during the past cycle and have been highly successful in obtaining
peer reviewed funding from NCI and/or other funding agencies. In addition, all past awardees have transitioned from
young investigators into leading academic positions and remain in the skin cancer field.
项目摘要-职业提升计划
职业提升计划(CEP)的目标是招聘、培训和留住多样化的优秀人才
致力于转化性皮肤癌研究的职业早期调查人员。CEP将由
由两名在基础(维拉纽瓦博士)和临床(维拉纽瓦博士)方面具有互补专业知识的知名研究人员组成。
Schuchter)黑色素瘤研究。两位联席主任都致力于培训和指导翻译
调查人员,并有招募和支持妇女和少数群体的既定记录。CEP将
主要协助初级教员的职业发展,但更有经验的调查人员感兴趣
也可以考虑将他们的研究重点重新放在黑色素瘤/皮肤癌上。女性和
将大力鼓励代表人数不足的少数群体参加。同样,旨在解决以下问题的项目
将鼓励健康差距和/或皮肤癌亚型在代表性不足的少数族裔中更为常见
并给予特别考虑。一支由临床医生、教育工作者和研究人员组成的团队,他们在
翻译研究将确保这一计划的具体目标的实施。在世界银行的支持下
宾夕法尼亚大学、艾布拉姆森癌症中心和维斯塔尔研究所,CEP将提供初级
教职员工需要的资源和指导,以建立创新的和全额资助的独立皮肤癌
研究项目,并成为未来的学术领袖。CEP将为获奖者提供两年的
为皮肤癌转化研究项目提供资金支持,并有可能推广到全孢子项目
或独立的赠款支持。获奖者需积极参与孢子功能,利用孢子
提供核心资源,并提供正式的书面进度报告和口头陈述。我们已经确立了
对研究导师的高标准和期望,以及正式的长期获奖者计划
师徒关系。该计划通过出版出版物、资金以及最终的职业生涯来衡量成功与否
进步和国家认可。我们拥有优秀的候选人人才库和一支有效的
培训和指导计划,将导致一组特殊的皮肤癌研究人员。我们的孢子
CEP在招募和培训转化性皮肤癌研究领域的研究人员方面有着出色的记录。
我们过去的CEP获奖者在上一个周期发表了74篇论文,并非常成功地获得了
来自NCI和/或其他资助机构的同行评审资金。此外,所有过去的获奖者都已从
年轻的研究人员进入领先的学术职位,并留在皮肤癌领域。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jessie Villanueva其他文献
Jessie Villanueva的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jessie Villanueva', 18)}}的其他基金
Targeting S6K2 to Overcome Drug Resistance in NRAS-mutant Melanoma
靶向 S6K2 克服 NRAS 突变黑色素瘤的耐药性
- 批准号:
10539830 - 财政年份:2022
- 资助金额:
$ 8.51万 - 项目类别:
Functional precision approaches to overcome intrinsic and acquired drug resistance in melanoma
克服黑色素瘤内在和获得性耐药性的功能精确方法
- 批准号:
10733196 - 财政年份:2017
- 资助金额:
$ 8.51万 - 项目类别:
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan
克服 BRAF 和 NRAS-mutan 固有耐药性的分子方法
- 批准号:
8634081 - 财政年份:2013
- 资助金额:
$ 8.51万 - 项目类别:
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan
克服 BRAF 和 NRAS-mutan 固有耐药性的分子方法
- 批准号:
9054086 - 财政年份:2013
- 资助金额:
$ 8.51万 - 项目类别:
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan
克服 BRAF 和 NRAS-mutan 固有耐药性的分子方法
- 批准号:
8826711 - 财政年份:2013
- 资助金额:
$ 8.51万 - 项目类别:
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan
克服 BRAF 和 NRAS-mutan 固有耐药性的分子方法
- 批准号:
9246446 - 财政年份:2013
- 资助金额:
$ 8.51万 - 项目类别:
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan
克服 BRAF 和 NRAS-mutan 固有耐药性的分子方法
- 批准号:
8488046 - 财政年份:2013
- 资助金额:
$ 8.51万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 8.51万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 8.51万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 8.51万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 8.51万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 8.51万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 8.51万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 8.51万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 8.51万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 8.51万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 8.51万 - 项目类别:
Research Grant














{{item.name}}会员




